• SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.56​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.80. The mean expectation of seventeen analysts for the quarter was for a loss of $1.51 per share. Wall Street expected results to range from $-2.44 to -99 cents per share.

• Revenue fell 83.6% to $12.82 million from a year ago; analysts expected $14.44 million.

• SAGE Therapeutics Inc's reported EPS for the quarter was a loss of $1.56​.

• The company reported a quarterly loss of $95.78 million.

• SAGE Therapeutics Inc shares had risen by 33.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.2% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 15 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.83

This summary was machine generated from LSEG data February 11 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)